Abstract
Background Thyroid tumor, as an endocrine tumor with increasing incidence, causes a heavy economic burden. Thyroid ultrasound is widely used for screening or diagnosis of thyroid tumors. However, false-positive thyroid ultrasound results can lead to misdiagnosis and wrong puncture biopsy, while false-negative thyroid ultrasound results can lead to missed diagnosis and delayed treatment. There is an urgent need to find a convenient, cost-effective and non-invasive diagnostic method to reduce the false-positive and false-negative rates of thyroid ultrasound. The aim of the present study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in thyroid cancer.
Patients and methods 843 subjects (malignant group, n=820; benign group, n=23) were finally included in this study. The remaining serum samples were collected and tested by YiDiXie ™ all-cancer detection kit. The sensitivity and specificity of YiDiXie™-SS were evaluated respectively.
Results The sensitivity of YiDiXie™-SS was 98.5% (95% CI: 97.5% - 99.2%) and its specificity was 65.2% (95% CI: 44.9% - 81.2%). This means that YiDiXie ™ -SS has an extremely high sensitivity and relatively high specificity in thyroid tumors.YiDiXie™-HS has a sensitivity of 84.3% (95% CI: 81.6% - 86.6%) and a specificity of 87.0% (95% CI: 67.9% - 95.5%). This means that YiDiXie™-HS has high sensitivity and specificity in thyroid tumors.YiDiXie™-D has a sensitivity of 75.5% (95% CI: 72.4% - 78.3%) and a specificity of 95.7% (95% CI: 79.0% - 99.8%). This means that YiDiXie™-D has relatively high sensitivity and very high specificity in thyroid tumors.The sensitivity of YiDiXie™-SS in patients with positive thyroid ultrasound was 98.4% (95% CI: 97.3% - 99.1%) and the specificity was 64.3% (95% CI: 38.8% - 83.7%). This means that the application of YiDiXie ™ -SS reduced the false-positive thyroid ultrasound rate by 64.3% (95% CI: 38.8% - 83.7%) with essentially no increase in malignant tumor underdiagnosis.The sensitivity of YiDiXie™-HS in thyroid ultrasound-negative patients was 90.0% (95% CI: 79.9% - 95.3%) and the specificity 88.9% (95% CI: 56.9%). (95% CI: 56.5% - 99.4%). This means that the application of YiDiXie™-HS reduced the false negative rate of thyroid ultrasound by 90.0% (95% CI: 79.9% - 95.3%).YiDiXie ™-D has a sensitivity of 75.3% (95% CI: 72.1% - 78.2%) and a specificity of 92.9% (95% CI: 68.5% - 99.6%) in patients with positive thyroid ultrasound. This means that YiDiXie™-D reduces the rate of false-positive thyroid ultrasounds by 92.9% (95% CI: 68.5% - 99.6%). YiDiXie™-D has a sensitivity of 78.3% (95% CI: 66.4% - 86.9%) and a specificity of 100% (95% CI: 70.1% - 100%) in patients with negative thyroid ultrasounds. This means that YiDiXie™-D reduces the false-negative rate of thyroid ultrasound by 78.3% (95% CI: 66.4% - 86.9%) while maintaining high specificity.
Conclusion YiDiXie™-SS has extremely high sensitivity and relatively high specificity in thyroid tumors.YiDiXie™-HS has high sensitivity and high specificity in thyroid tumors.YiDiXie ™ -D has relatively high sensitivity and extremely high specificity in thyroid tumors. YiDiXie™-SS significantly reduces thyroid ultrasound false-positive rates with essentially no increase in delayed treatment for thyroid cancer.YiDiXie ™ -HS significantly reduces thyroid ultrasound false-negative rates.YiDiXie™-D significantly reduces thyroid ultrasound false-positive rates or significantly reduces its false-negative rates while maintaining high specificity. YiDiXie™ tests have vital diagnostic value in thyroid cancer, and are expected to solve the problems of “high false-positive rate” and “high false-negative rate” of thyroid ultrasound.
Clinical trial number ChiCTR2200066840.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200066840
Funding Statement
This work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The results were updated. Most tabels and results were reviesed.
Data Availability
All data produced in the present study are contained in the manuscript.